Indena Enhances Developments in Custom Synthesis
Indena is completing the construction of a new GMP kilolab for highly potent APIs.
Indena has completed the construction of a new GMP kilolab for highly potent APIs (HPAPIs). The suite is designed to handle substances requiring an occupational exposure limit (OEL) between 20 and 50 ng/m3. With the new high-containment kilolab, Indena will have the technical capacity to handle a greater range of compound classes, including derivatives from fermentation and total synthesis. Indena remains firmly attached to its know-how of natural and semi-synthetic substances, but with the high-containment facility built for the production of highly toxic active ingredients, the company will be able to extend its range of custom synthesis. Indena will be exhibiting at CPhI Worldwide, in Frankfurt, Germany from October 24–26, 2017.
Source: Indena, Booth 8.0F30
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
